- Menu
- 1. Recommandations sur la prise en charge de l’hypertension: bénéfices et risques
- 2. May 2017, le mois de la mesure
- 3. Bénéfices/risques
- 4. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
- 5. Comparaison des catégories d’hypertension selon les recommandations américaines et européennes.
- 6. Impact du changement de normes
- 7. Schematic overview
- 8. "Labelling" effect
- 9. The 2018 ESC/ESH guidelines
- 10. New concepts
- 11. BP measurement
- 12. Automated compared to manuel office blood pressure and to home blood pressure in hypertensive patients
- 13. Unattended BP Measurements in SPRINT
- 14. ESC
- 15. Evaluation du risque cardiovasculaire à 10 ans selon le système SCORE
- 16. Evaluation du risque cardiovasculaire à 10 ans selon le système SCORE
- 17. Evaluation du risque cardiovasculaire à 10 ans selon le système SCORE
- 18. Summary of office blood pressure thresholds for treatment
- 19. Initiation of BP-lowering treatment
- 20. Office BP treatment targets in hypertensive patients
- 21. Office blood pressure treatment target ranges
- 22. BP reduction with two different drugs separately
- 23. Percentage of patients with normal blood pressure using ARB + CCB/or D
- 24. Triple combination therapy enables better BP control compared with dual therapies
- 25. ESC
- 26. Initial mono vs combination treatment the lombardy database
- 27. SPCs have several advantages vs. free combinations of two or more antihypertensive drugs
- 28. Changes in home systolic BP in the 3 treatment regimens and the 3 phases in PATHWAY 1
- 29. Drug-treatment strategy for hypertension and CKD
- 30. New concepts
- 31. Drug adherence with fixed doses combinations
- 32. Interventions that may improve druf adherence in hypertension
- 33. Interventions that may improve druf adherence in hypertension (2)
- 34. Interventions that may improve druf adherence in hypertension (3)
- 35. Risques et choses à ne pas faire !
- 36. ESC
- 37. Hypertension chez la personne âgée
- 38. ESC
- 39. ESC
- 40. Relationships of Numbers of Outcomes Prevented and Numbers of Excess in Treatment Discontinuation
- 41. Primary and Secondary Outcomes and Renal Outcomes
- 42. Serious Adverse Events
- 43. Renal adverse effects
- 44. Conclusions